AUS
NZ
UK
CA
USA
IND
_06_03_2026_21_29_34_162131.jpg)
Summary
- Vaccine related stocks have gained a lot of attention due to the pandemic; however other pharmaceutical and biotechnology stocks have faced volatility.
- The focus has been primarily on companies having high levels of research and development capabilities.
Pharmaceuticals and biotechnology stocks have gained attention in recent times, especially vaccine related stocks, due to their contribution in the fight against the pandemic. But, aside from pharma giants, the rest of the pharmaceutical and biotechnology sector has been facing some extent of volatility as the focus has been primarily on companies having high levels of research and development capabilities, among other factors.
In this article, we would take a look at 3 FTSE AIM All Share stocks in the pharmaceuticals and biotechnology sector that have given returns of over 100 per cent:
- Agronomics Ltd (LON:ANIC)
FTSE AIM All Share listed biotechnology firm Agronomics is UK’s leading listed alternative protein company. Today it announced a secondary purchase of shares in Dutch food production company Meatable.
Agronomics bought a further 117 shares worth EUR 195,632, which now brings its shareholding to 4,859 shares in Meatable and equity ownership of 5.84 per cent in the meat company.
(Source: EODHD/Others, Thomson Reuters)
The company’s shares were trading at GBX 23.90, down by 0.42 per cent as of 13 May at 10:37 hrs GMT+1, while the medicine and biotech sectoral index stood at 16,240.09, down by 1.00 per cent.
Agronomics has a current market capitalisation of £120.45 million and a one-year return of 258.15 per cent.
Also Read: A Glance at 5 Healthcare Penny Stocks
- E-Therapeutics PLC (LON:ETX)
E-Therapeutics came up with its final audited results for FY 2021 ending 30 January today.
The company reported that its revenues fell to £0.3 million from £0.5 million in FY 2020, while its operating losses improved from £2.9 million in FY 2020 to £4.5 million in FY 2021. It also raised total gross funds worth up to £13.2 million in the FY2021.
(Source: EODHD/Others, Thomson Reuters)
The company’s shares were trading at GBX 27.00, down by 6.25 per cent as of 13 May at 10:34 hrs GMT+1, while the broader index FTSE AIM All Share stood at 1,215.10, down by 1.42 per cent.
E-Therapeutics has a current market capitalisation of £121.18 million, and its one-year return stood at 104.87 per cent.
- Sareum Holdings PLC (LON:SAR)
UK based Sareum Holdings is also listed on the FTSE AIM All share index. The drug discovery company mainly focuses on cancer related small molecule therapeutics. Sareum announced on 13 May exercised share options for over 3,000,000 new ordinary shares worth 0.25 pence per share and with an exercise price of 0.6 pence per share.
(Source: EODHD/Others, Thomson Reuters)
The company’s shares were trading at GBX 2.38, down by 3.06 per cent as of 13 May at 10:42 hrs GMT+1. Sareum Holdings has a current market capitalisation of £80.06 million and a one-year return of 203.25 per cent.
Also Read: Quick Review of Two AIM Listed Stocks: Altus Strategies PLC & Sareum Holdings PLC
